|
WO2020219876A1
|
|
Ionizable amine lipids and lipid nanoparticles
|
|
WO2020198706A1
|
|
Compositions and methods for ttr gene editing and treating attr amyloidosis comprising a corticosteroid or use thereof
|
|
TW202102529A
|
|
Polynucleotides, compositions, and methods for polypeptide expression
|
|
WO2020198697A1
|
|
Compositions and methods comprising a ttr guide rna and a polynucleotide encoding an rna-guided dna binding agent
|
|
WO2020118041A1
|
|
Modified amine lipids
|
|
TW202027797A
|
|
Compositions and methods for treating alpha-1 antitrypsin deficiency
|
|
WO2020082041A1
|
|
Nucleic acid constructs and methods of use
|
|
TW202027798A
|
|
Compositions and methods for transgene expression from an albumin locus
|
|
US2020289628A1
|
|
Compositions and methods for expressing factor ix
|
|
WO2020081613A1
|
|
Compositions and methods for immunotherapy
|
|
WO2020072605A1
|
|
Ionizable amine lipids
|
|
WO2020069296A1
|
|
Compositions and methods for lactate dehydrogenase (ldha) gene editing
|
|
TW202020156A
|
|
Compositions and methods for hydroxyacid oxidase 1 (hao1) gene editing for treating primary hyperoxaluria type 1 (ph1)
|
|
WO2019237069A1
|
|
Modified guide rnas for gene editing
|
|
AR115505A1
|
|
MODIFIED GUIDELINES FROM RNA FOR GENE EDITING
|
|
WO2019237035A1
|
|
Compositions and methods for immunooncology
|
|
CN111405912A
|
|
Polynucleotides, compositions and methods for genome editing
|
|
EP3688161A1
|
|
Compositions and methods for ttr gene editing and treating attr amyloidosis
|
|
CA3077391A1
|
|
In vitro method of mrna delivery using lipid nanoparticles
|
|
CA3077413A1
|
|
Formulations
|
